Advancing Precision Medicine in Lung Cancer: Integrating Genomics, Liquid Biopsy and Novel Diagnostic Tools

Precision medicine in the context of lung cancer represents a transformative approach that integrates prevention, diagnosis, and treatment tailored to individual patient differences. This field leverages large datasets, including genomic information and electronic health records, to customize healthcare strategies. Despite advancements, current clinical practices still require robust algorithms, protein biomarkers, and gene signatures to predict early-stage lung cancer and optimize therapeutic responses. Recent studies have highlighted the potential of liquid biopsy as a non-invasive diagnostic tool, capable of identifying circulating tumor cells and cell-free DNA, although its sensitivity varies with testing platforms and tumor extent. The emergence of next-generation sequencing (NGS) has furthered our understanding of somatic mutations in lung cancer, providing insights into the mutational landscape and facilitating the development of targeted therapies. However, challenges remain in ensuring comprehensive testing and access to personalized treatments, as outlined by the National Comprehensive Cancer Network (NCCN) guidelines, which emphasize the importance of targeted therapies and immunotherapy for specific lung cancer subtypes.

This Research Topic aims to explore advanced approaches in precision medicine for lung cancer, focusing on enhancing diagnostic tools and identifying new therapeutic targets to improve patient outcomes. The objective is to address critical questions regarding the integration of genomic data into clinical practice, the development of novel biomarkers, and the optimization of treatment strategies for lung cancer patients. By investigating these areas, the research seeks to contribute to the ongoing transformation of lung cancer care, ultimately improving the quality of life for patients through more personalized and effective interventions.

To gather further insights in the realm of precision medicine and lung cancer theragnostic, we welcome articles addressing, but not limited to, the following themes:

• Precision medicine and lung cancer theragnostic
• Genetics and genomics in lung cancer
• Targeted drug therapy and biomarkers
• New techniques for improved cancer diagnosis and treatment
• Liquid biopsy and the future of diagnostic approaches
• Future perspectives in the era of precision medicine